(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How one man's concern saved his brothers from heart disease - 2Commonsense Ways to work on Your Funds with a Restricted Pay
- 3Scientists document a death from a meat allergy tied to certain ticks
- 4Overseeing Individual budgets Successfully
- 5Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
- Brazil's agricultural research agency gets cannabis research greenlight
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Satellite space quiz: What's orbiting Earth?
- They want better health care — so they're turning to crypto startups
- How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- Why this Tennessee special election has the 'whole world' watching
